---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-193913"
form_type: "8-K"
ticker: "SPRO"
cik: "0001701108"
company_name: "Spero Therapeutics, Inc."
filed_at: "2024-08-05T23:59:59+00:00"
generated_at: "2026-05-31T13:09:21.767709+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Spero Therapeutics Q2 net loss $17.9M; CMO departs; SPR720 data expected 4Q 2024

## Summary
- Net loss $17.9M ($0.33/share) vs $11.9M loss ($0.23) in Q2 2023; revenue $10.2M up from $2.7M.
- Cash $63.5M as of June 30, 2024; runway into late 2025 reaffirmed.
- SPR720 Phase 2a NTM-PD trial enrollment completed; preliminary data expected 4Q 2024.
- CMO Kamal Hamed departing Aug 29; Board member John Pottage appointed Special Advisor to oversee medical function.
- Tebipenem HBr Phase 3 PIVOT-PO enrollment on track; target ~2,648 patients, completion H2 2025.

## SEC filing metadata
- accession: 0001193125-24-193913
- form_type: 8-K
- ticker: SPRO
- cik: 0001701108
- company_name: Spero Therapeutics, Inc.
- filed_at: 2024-08-05T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1701108/000119312524193913/0001193125-24-193913-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1701108/000119312524193913/d871341d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-193913
- JSON: https://secwatch.observer/filing/0001193125-24-193913.json
- Plain text: https://secwatch.observer/filing/0001193125-24-193913.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.